Arguably, pharmacological interventions directed to the stabilization of the β-Catenin destruction complex might represent an amenable therapeutic strategy to counteract the formation of a tumor conducive immune response involved in local tumor progression and distant metastatic diffusion in those breast tumors, exemplified by BC tumors with low p140Cap expression, that display alteration of the β-Catenin signaling pathway. The gene discussed is SRCIN1; the disease is neoplasm.